Expression of NUF2 and CD52 and Their Correlation With Chemotherapy Resistance and Prognosis in Patients With Non‐Small Cell Lung Cancer

Lung cancer is one of the most common malignant tumors. This study aim to investigate the expression of cell division related gene cell division cycle related protein 2 (NUF2) and immune-related gene CD52 in patients with non-small cell lung cancer (NSCLC) and their correlation with chemotherapy resistance and clinical prognosis. The cancer tissues and adjacent tissues of 72 patients with NSCLC were collected. According to the staining results, the patients were divided into NUF2 positive and negative expression groups, and CD52 positive and negative expression groups. The relationship of NUF2 and CD52 with clinicopathological features and chemoresistance was analyzed. The patients were followed up for 5 years, and Kaplan-Meier survival curve was used to analyze the relationship. COX regression analysis was used to analyze the risk factors. The positive expression rate of NUF2 in NSCLC tissues was 66.67% (48/72), which was significantly higher than 38.89% (28/72) in adjacent tissues (p < 0.05). The positive expression rate of CD52 in NSCLC tissues was also higher than the adjacent tissues (p < 0.05). NUF2 expression was related to the degree of differentiation, TNM stage, lymph node metastasis and pleural invasion in NSCLC patients (p < 0.05). The expression of CD52 was related to TNM stage, lymph node metastasis, vascular tumor thrombus and pleural invasion (p < 0.05). The median survival time of patients with positive CD52 and NUF2 expression was lower than patients with negative expression (p < 0.05). Platinum-resistance, lymph node metastasis, pleural invasion, NUF2 and CD52 positive expression were independent risk factors for poor prognosis of NSCLC (p < 0.05). In conclusion, NUF2 and CD52 are independent risk factors for poor prognosis of patients with NSCLC. They may be used as one of the indicators to evaluate drug resistance and prognosis of patients.